KRAS and non-small cell lung carcinoma: Interestingly, since it is of strong interest to look more specifically for the KRAS p.G12C mutation for possible selection of metastatic NSCLC patients for AMGG510 or MTRX89 therapeutic strategies, one recent study showed the feasibility of detection of this mutation from cf-DNA with a high specificity and sensitivity at baseline [48].